The different pattern of blood S100B protein and GFAP concentrations in ischemic stroke

  • Yenny Surjawan Faculty of Medicine, University of Hasanuddin, Makasar, Indonesia
  • Suryani As’ad Faculty of Medicine, University of Hasanuddin, Makasar, Indonesia
  • Teguh A.S. Ranakusuma Department of Neurology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Andi Wijaya Faculty of Medicine, University of Hasanuddin, Makasar, Indonesia
Keywords: GFAP, ischemic stroke, NIHSS, S100B protein
Abstract viewed: 1493 times
PDF downloaded: 645 times


Background: S100B protein and glial fibrillary acidic protein (GFAP) released during ischemia have been associated with stroke. This study aimed to know whether there was a correlation between the concentration of these markers with the severity of neurological deficit in ischemic stroke.

Methods: This was a cross-sectional study, which involved 143 ischemic stroke patients who were admitted to hospital not more than 72 hours after the onset and fulfilled the criteria. The concentration of S100B protein and GFAP was determined by ELISA method. Blood level of S100B and GFAP in patient with mild, moderate, and severe stroke were analyzed with Kruskal-Wallis test.

Results: There was a significant difference between S100B protein concentration among subjects with mild (median 63.31 ng/L), moderate (median 88.93 ng/L), and severe (median 511.55 ng/L) NIHSS at admission (p < 0.05). A weak significant correlation was found between the severity of NIHSS and the S100B protein concentration. The more severe the NIHSS, the higher the S100B protein concentration (r = 0.351; p < 0.001). Subjects with moderate and severe NIHSS were more frequent to have an intermediate or high level of S100B protein than the subjects with mild NIHSS (OR = 3.9; p < 0.001). The median concentration of GFAP was significantly higher in severe NIHSS subjects (median 0.374 ng/mL) than its concentration in mild (median 0.047 ng/mL) and moderate (median 0.043 ng/mL) NIHSS subjects (p < 0.05).

Conclusion: S100B protein concentration was significantly higher in linier relation with the severity of NIHSS, while the GFAP concentration was significantly higher if the NIHSS had been already severe. (Med J Indones. 2013;22:215-20. doi: 10.13181/mji.v22i4.602)

Keywords: GFAP, ischemic stroke, NIHSS, S100B protein


Download data is not yet available.


  1. Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke. 2004;35(1):57-63.

  2. Whiteley W, Tseng MC, Sandercock P. Blood biomarker in the diagnosis of ischemic troke: A systematic review. Stroke. 2008;39:2902-9.

  3. Endres M, Dirnagil U, Moskowitz MA. The ischemic cascade and mediators of ischemic injury. 2009. In: Fisher M, editor. Handbook of clinical neurology, vol 92 (3rd series) Stroke. Part I. Boston: Elsevier; 2009. p. 31-41.

  4. Graham SH, Hickey RW. Molecular pathophysiology of stroke. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: the fifth generation of progress. Pennsylvania: American College of Neuropsychopharmacology. 2002. p. 1317-26.

  5. Lakhan EL, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: theraupetic approaches. J Transl Med. 2009;7:97-107.

  6. Saenger AK, Christenson RH. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem. 2010;56(1):21-33.

  7. Hill MD. Diagnostic biomarkers for stroke: a stroke neurologist's perspective. Clin Chem. 2005;51(11):2001-2.

  8. Jauch ECJ. Biomarker advances in acute ischemic stroke. In: Advancing the Standard of Care: Cardiovascular and Neurovascular Emergencies. Division of Emergency Medicine, Washington University School of Medicine, Cincinnati; 2005

  9. Jickling G, Xu H, Sharp F. Biomarkers of ischemic stroke. US Neurology. 2009;5:52-4.

  10. Liswaty E, Wijaya A, Ranakusuma TAS. Biochemical markers for differential diagnosis of stroke: a biochemical marker study of S100B protein, neuron specific enolase (NSE), myelin basic protein (MBP), and heart-type fatty acid binding protein (H-FABP). Indonesian Biomedical Journal. 2009;1:68-72.

  11. Buttner T, Weyers S, Postert T, Sprengelmeyer R, Kuhn W. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke. 1997;28(10):1961-5.


  13. Missler U, Wiesmann M, Wittmann G, Magerkurth O, Hagenstrom H. Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem. 1999;45(1):138-41.

  14. Wunderlich, MT, Ebert AD, Kratz T, Goertler M, Jost S, Herrmann M. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke. 1999;30(6):1190-5.

  15. Herrmann M, Vos P, Wunderlich MT, de Bruijn CHMM, Lamers KJB. Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentration of protein S-100B and glial fibrillary acidic protein. Stroke. 2000;31(11):2670-7.

  16. Ali MS, Harmer M, Vaughan R. Serum S100 protein as a marker of cerebral damage during cardiac surgery. Br J Anaesth. 2000;85(2):287-98.

  17. Michetti F, Gazzolo D. S100B Protein in biological fluids: a tool for perinatal medicine. Clin Chem. 2002;48(12):2097-104.

  18. Yu ACH, Wong HK, Yung HW, Lau LT. Ischemia â induced apoptosis in primary cultures of astrocytes. Glia. 2001;35(2):121-30.

  19. Sofroniew MV, Vinters HV. Astrocytes: Biology and pathology. Acta Neuropathol. 2010;119(1):7-35.

  20. Foerch C, Curdt I, Yan B, et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J. Neurol. Neurosurg. Psychiatry. 2006;77(2):181-4.

How to Cite
Surjawan Y, As’adS, Ranakusuma TA, Wijaya A. The different pattern of blood S100B protein and GFAP concentrations in ischemic stroke. Med J Indones [Internet]. 2013Dec.13 [cited 2024Jul.16];22(4):215-20. Available from:
Clinical Research